Veins of gold

[georgethenight2]

are most likely not related to Afrezza. As the deadline for Trep T has most investors sitting on needles, the question remains, how will MC focus this income stream? Although the NDA is not 100 percent, the idea that it does not receieve the green light is...heart wrenching!

I still think Afrezza has potential, but if we can create multiple UTHR like relationships I think this would be easier, given out track record with Afrezza.

[prcgorman2]

“Veins of gold”. It is so sad how many times somebody well placed in Mannkind has used hyperbole only to have to eat their words. “Epic”, and “veins of gold” being two of the more well remembered badly chosen phrases, at least so far. I really respected Dr. Kendall, but didn’t like his choice of words. It felt strained to me. I think he did see information that could be teased out of previous study results and of course his team did publish some papers, which I assume were generally well receved, but didn’t really move the needle with prescribers. I am interested to see whether Afrezza ever takes off. If it does, Dr. Kendall will look very good. And I think Afrezza should sell really well, eventually, because it really is the best prandial insulin on the market, bar none. It’s safety and efficacy are unquestionable. Prove that with a well designed trial or two, get a better label, improve the insurance coverage, lower the price, and Katy bar the door.